Experimental compounds that alter RNA boost the effectiveness of immunotherapy drugs against cancer cells and could potentially extend their use to more patients, suggests a study in mice from the… Read More
The age of molecular-scale computing is entering a new era, thanks to the development of a system that uses synthetic proteins and Boolean logic to identify cancer cells. The proteins… Read More
Seattle’s Infectious Disease Research Institute and a New Jersey company called Celularity have been cleared by the Food and Drug Administration to start trials of an experimental cell-based therapy for… Read More
Researchers at Seattle’s Fred Hutchinson Cancer Research Center have demonstrated the effectiveness of a new method for getting immune cells to fight solid tumors — by spreading them like jam… Read More
Maryn Sage remembers the words she heard on the day she learned that her 16-year-old son, Jedd Feliciano, was cancer-free. “His marrow’s clean,” the doctor told her over the phone,… Read More
Two months after Merck acquired Seattle-based biotech Immune Design for $300 million, the president of Merck Research Laboratories, Roger Perlmutter, says the city’s life science community has plenty more to… Read More
Merck, one of the world’s largest drugmakers, agreed to buy Seattle-based biotechnology company Immune Design for $300 million in cash. The deal’s price tag, at $5.85 per share, amounted to… Read More
Things are a little on edge in Seattle’s biotech scene after the Jan. 3 announcement that pharmaceutical giant Bristol-Myers Squibb (BMS) intends to buy Celgene, the parent company of Juno… Read More
In science, it was the best of times, and the worst of times. 2018 was a year when researchers focused in on ways to head off disease by reprogramming a… Read More
Seattle-based biotech startup Kineta today received a leg-up in its efforts to kill cancerous tumors using the immune system. Kineta announced an agreement with drug giant Pfizer that includes $15 million in… Read More
Billionaire philanthropist Paul Allen died two months ago, but before he passed away, he passed along a $125 million commitment to a new research frontier: the Allen Institute for Immunology.… Read More
BELLEVUE, Wash. — Cancer treatments have improved astronomically in the past few decades. But as more patients overcome the disease, a different monster is rearing its head: financial toxicity. “Most… Read More
Few advances in cancer treatment have gotten as much attention in the past decade as immunotherapies, therapies that use the immune system to fight the disease. Various immunotherapies have wiped… Read More
OncoResponse, a Seattle biotech company creating antibody-based treatments for cancer, has raised a $40 million Series B round to advance five new treatments into preclinical and clinical trials. The company… Read More
The emerging form of cancer treatment called CAR T immunotherapy is wiping out the disease in some terminal patients — but despite early successes, the treatments still have major drawbacks. Many… Read More
Nearly 40 years ago, scientists had what seemed like a crazy idea: What if we could reprogram cancer patients’ immune systems to wipe out their disease? It turns out the… Read More
Seattle Children’s Research Institute is launching a clinical trial that will examine a new kind of cancer-fighting treatment. The treatment is a type of CAR T immunotherapy, which reprograms a… Read More
CAR T immunotherapies are one of the hottest topics of research — and investment — in the world of medicine today. The emerging treatments have had shocking success in the past few years,… Read More
Seattle startup Aminex Therapeutics announced $10 million in new funding Wednesday, alongside the first clinical trial of its immunotherapy drug. The drug will be studied as a treatment for multiple… Read More
When Avery Berg was diagnosed with aggressive, late-stage brain cancer at just 10 years old, she fought hard to stay positive and beat the disease with a smile. “I didn’t… Read More
New cancer immunotherapies could revolutionize how we treat the disease, but for many children, those treatments are far out of reach. A new collaboration between four children’s hospitals across North… Read More
In 2008, Emmanuel Akporiaye left a tenured position at the University of Arizona to move across the country and launch a new biotechnology startup, aiming to make a less toxic… Read More
Hans Bishop, the co-founder and longtime CEO of immunotherapy company Juno Therapeutics, has quietly left that role following the company’s $9 billion acquisition by biotech giant Celgene, he told GeekWire… Read More
On a chilly Monday morning in January, Seattle awoke to the news that one of its most promising companies, Juno Therapeutics, reached a deal to be acquired by biotech giant… Read More
PITTSBURGH — Far before humans understood the basics of modern medicine, our immune systems protected our bodies from microscopic invaders and battled deadly diseases. Now, scientists in the emerging field… Read More
Seattle Genetics, a biotechnology company that develops antibody-based cancer treatments, announced Wednesday that it will acquire Cascadian Therapeutics and the company’s small-molecule breast cancer treatment for about $614 million, or… Read More
When Celgene announced Monday that it will acquire Seattle-based biotech Juno Therapeutics for $9 billion, the development was a surprise to many — including some inside Juno itself, according to… Read More
New Jersey-based biotech giant Celgene is in talks to buy Seattle-based biotech Juno Therapeutics, according to a report in the Wall Street Journal. Juno’s stock rose more than 50 percent… Read More
A study conducted by Fred Hutchinson Cancer Research Center, with contributions from researchers across North America, has found stark differences between children and adults with acute myeloid leukemia (AML), a… Read More
Eric Dobmeier, the longtime COO at public biotech company Seattle Genetics, is stepping down from his role to become CEO at stealthy biotech startup Silverback Therapeutics, GeekWire has learned. Dobmeier will… Read More